Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines

Authors:
Publisher website
Google Scholar
Abstract
In the third year of the coronavirus disease 2019 (Covid-19) pandemic, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the globe and yielded several subvariants.1,2 Currently, BA.2 is overtaking BA.1 in frequency. In addition, BA.2.12.1 infection is increasing quickly and already accounts for more than 50% of new infections in the United States. Therefore, the protection of current vaccines and the need to develop future vaccination strategies are of great concern.
Funding Information
  • National Key R&D Program of China (2020YFA0509202, 2020YFA0907102)
  • the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010202)
  • National Natural Science Foundation of China (81991494, 82122031)
  • Bill and Melinda Gates Foundation (INV-006377)
  • Beijing Nova Program of Science and Technology (Z191100001119030)
  • Youth Innovation Promotion Association of the CAS (2018113, 2020092)